source
- Capricor sues Japanese partner over botched Duchenne therapy launch and pricing concernsCapricor Therapeutics has filed a lawsuit against its Japanese collaborator Nippon Shinyaku and its subsidiary NS Pharma. The biotech alleges the partners mishandled preparations for the launch of…
- Odyssey Therapeutics raises $279 million in IPO, begins Nasdaq tradingOdyssey Therapeutics, a biotech focused on autoimmune diseases, announced that its initial public offering generated $279 million. The company sold about 15.5 million shares and priced the IPO at…